Research analysts at Stifel Canada reduced their Q4 2024 earnings estimates for Kinross Gold in a report issued on Tuesday, ...

Stifel Financial Corp (NYSE:SF). has announced a revision to its executive compensation structure, according to a recent SEC filing. On Monday, the Compensation Committee of the Board of Directors ...

The gross proceeds from the initial public offering are expected to be approximately $191 million, before deducting underwriting discounts and commissions and other offering expenses, and excluding ...

We recently compiled a list of the 12 Trending AI Stocks on Latest News and Ratings. In this article, we are going to take a look at where International Business Machines Corporation (NYSE:IBM) ...

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such ...

The team of three advisors have started a firm called T6 Wealth Management, which will operate out of Morgan Stanley's new ...

Stifel analysts reiterated their Buy rating for Arcellx Inc. (NASDAQ: ACLX) with a consistent price target of $122.00. Currently trading at $64.01, the stock has significant upside potential according ...

We may earn an affiliate commission from links. Is it any wonder there are so many iconic New York movies? At the best of times, life in the city that never sleeps can be disarmingly cinematic ...

On this week's episode of the Stifel Snow Show, two-time defending Olympic champion Chloe Kim got back to her gold medal level on the halfpipe, Jessie Diggins battled through injury for another ...

In a report released yesterday, Matthew Smith, CFA from Stifel Nicolaus maintained a Hold rating on Hain Celestial (HAIN – Research Report), ...

Stifel Financial (SF) CEO Ron Kruszewski sits down with Yahoo Finance Executive Editor Brian Sozzi in Davos, Switzerland, at the 2025 World Economic Forum to discuss his market (^DJI,^GSPC, ^IXIC ...

Stifel has initiated coverage of Cytokinetics (NASDAQ:CYTK) with a buy rating, citing its drug aficamten. The bank noted the stock was "out of favor" in the wake of a "controversial" deal with ...